Stay updated on Pembrolizumab for Intermediate Risk NMIBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.

Latest updates to the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe page's revision stamp was updated from v3.6.3 to v3.6.4, replacing the previous revision with a newer version.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe page revision label was updated to v3.6.3, and older revision text along with links such as 'Bladder cancer' and 'MedlinePlus Genetics' were removed.SummaryDifference0.2%

- Check36 days agoChange DetectedThe page now displays Revision: v3.6.2, replacing the previous v3.6.0. This reflects a minor version update to the page template.SummaryDifference0.1%

- Check50 days agoChange DetectedRecruitment status shows no longer looking for participants. New user guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) have been added, the Intervention/Treatment header formatting updated (from 'Intervention / Treatment' to 'Intervention/Treatment'), and the revision tag updated to v3.6.0.SummaryDifference0.5%

- Check58 days agoChange DetectedThe page footer now displays Revision: v3.5.5, replacing the previous Revision: v3.5.4. This indicates a small software update to the site.SummaryDifference0.1%

- Check65 days agoChange DetectedThe page no longer displays links or sections for bladder cancer, related topics, and MedlinePlus Genetics, reducing navigational references to these topics on the study page.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab for Intermediate Risk NMIBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.